Depakote ER

ApprovedSmall molecule

Mylan Pharmaceuticals Inc

Depakote ER is one of 149 small molecule programs targeting Mood Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mood DisorderActive, not recruiting

Borderline Personality DisorderActive, not recruiting

Alcohol AbuseActive, not recruiting

EpilepsyActive, not recruiting

DementiaActive, not recruiting

Mood DisorderApproved

Active, not recruiting

Borderline Personality DisorderPreclinical

Active, not recruiting

Alcohol AbusePhase 2

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

DementiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

Briviact

UCB

Phase 3

14 2

Dayvigo

Eisai

Phase 3

1 3

Depakote ER

Mylan Pharmaceuticals Inc

Approved

1 4

Fintepla

IImmedica Pharma AB

Phase 3

4 5

Actemra

Roche

Phase 3

—6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 7

Narcan

SScienture

Phase 3

1 8

GWP42003-P

Jazz Pharmaceuticals

Phase 3

1 9

Immunoglobulin

Sanofi

Phase 3

1 10

Akineton

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bipolar Depression2 trials

Depakote ER in Bipolar Depression

Completed·SStanford University·Phase 4·NCT00186186·28 enrolled

Depakote-ER for Depressive and Bipolar Depression

Completed·CCambridge Health Alliance·Phase 4·NCT00226343·25 enrolled

Borderline personality disorder1 trial

Depakote ER in Borderline Personality Disorder

Completed·UUniversity of Minnesota·N/A·NCT00222482·15 enrolled

Mood Disorder1 trial

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177567·60 enrolled

Dementia1 trial

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

Terminated·TTuscaloosa Research & Education Advancement Corporation·Phase 3·NCT00315900·20 enrolled

Efficacy1 trial

A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR

Completed·MMassachusetts General Hospital·Phase 4·NCT00334347·5 enrolled

3 more indications

Epilepsy1 trial

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

Completed·AAbbott·Phase 2·NCT00646711·16 enrolled

Alcohol Abuse1 trial

Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

Withdrawn·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT00204503

Unspecified2 trials

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00647712·38 enrolled

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648076·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Depakote ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depakote ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depakote ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mylan Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Mylan Pharmaceuticals Inc

Depakote ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bipolar Depression2 trials

Borderline personality disorder1 trial

Mood Disorder1 trial

Dementia1 trial

Efficacy1 trial

Epilepsy1 trial

Alcohol Abuse1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News